$MLRT
Metalert, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224045769 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $52.03K
YoY Change -39.32%
Cost Of Revenue $32.72K
YoY Change -61.81%
Gross Profit $19.31K
YoY Change 24981.82%
Gross Profit Margin 37.12%
Selling, General & Admin $63.15K
YoY Change -10.56%
% of Gross Profit 326.98%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $153.1K
YoY Change -39.62%
Operating Profit -$133.7K
YoY Change -47.22%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$64.09K
YoY Change -63.62%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$197.8K
YoY Change -53.95%
Net Earnings / Revenue -380.24%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.01
COMMON SHARES
Basic Shares Outstanding 34.75M shares 34.35M shares
Diluted Shares Outstanding 34.19M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.96K
YoY Change -72.0%
Cash & Equivalents $29.31K
Short-Term Investments $649.00
Other Short-Term Assets $4.079K
YoY Change -14.47%
Inventory $225.4K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $283.7K
YoY Change -34.11%
LONG-TERM ASSETS
Property, Plant & Equipment $11.16K
YoY Change -67.29%
Goodwill
YoY Change
Intangibles $219.9K
YoY Change -21.32%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $231.0K
YoY Change -26.32%
TOTAL ASSETS
Total Short-Term Assets $283.7K
Total Long-Term Assets $231.0K
Total Assets $514.7K
YoY Change -30.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $198.1K
YoY Change -3.81%
Accrued Expenses
YoY Change
Deferred Revenue $7.646K
YoY Change 18.54%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.624M
YoY Change 11.13%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.624M
Total Long-Term Liabilities
Total Liabilities $4.757M
YoY Change 10.65%
SHAREHOLDERS EQUITY
Retained Earnings -$29.35M
YoY Change 3.18%
Common Stock $3.435K
YoY Change 7.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.243M
YoY Change
Total Liabilities & Shareholders Equity $514.7K
YoY Change -30.83%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$197.8K
YoY Change -53.95%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34345931 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34345931 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32445931 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32445931 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
3435 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3245 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
25103322 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24844494 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29349463 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28746629 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4242684 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3898874 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
514731 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
610195 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52028 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11159 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7646 usd
CY2024Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
89886 usd
CY2024Q3 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
16778 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
207272 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
52779 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
159344 usd
us-gaap Gross Profit
GrossProfit
91730 usd
us-gaap Gross Profit
GrossProfit
47928 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
197261 usd
us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
363359 usd
us-gaap Professional Fees
ProfessionalFees
113917 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16263 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
183685 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
178690 usd
us-gaap Operating Expenses
OperatingExpenses
489074 usd
us-gaap Operating Expenses
OperatingExpenses
661318 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-397344 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-613390 usd
MLRT Gain On Settlement Of Debt
GainOnSettlementOfDebt
44217 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
24917 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
63247 usd
MLRT Interest Expense Income And Financing Costs
InterestExpenseIncomeAndFinancingCosts
-180573 usd
MLRT Interest Expense Income And Financing Costs
InterestExpenseIncomeAndFinancingCosts
-254836 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-205490 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-273901 usd
us-gaap Net Income Loss
NetIncomeLoss
-602834 usd
us-gaap Net Income Loss
NetIncomeLoss
-887291 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-602834 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-887291 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001375793
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 MLRT Gain On Settlement Of Debt
GainOnSettlementOfDebt
usd
CY2023Q3 MLRT Gain On Settlement Of Debt
GainOnSettlementOfDebt
usd
MLRT Gain On Settlement Of Debt
GainOnSettlementOfDebt
usd
CY2024Q3 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
usd
CY2023Q3 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
usd
CY2024Q3 MLRT Issuance Of Preferred Stock For Financings
IssuanceOfPreferredStockForFinancings
usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
usd
MLRT Gains Losses On Settlement Of Debt And Accrued Interest
GainsLossesOnSettlementOfDebtAndAccruedInterest
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
MLRT Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
MLRT Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53046
dei Entity Registrant Name
EntityRegistrantName
MetAlert, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0493446
dei Entity Address Address Line1
EntityAddressAddressLine1
117 W. 9th Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1214
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90015
dei City Area Code
CityAreaCode
(213)
dei Local Phone Number
LocalPhoneNumber
489-3019
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001
dei Trading Symbol
TradingSymbol
MLRT
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34745931 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29308 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68440 usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
24297 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
17408 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
225351 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
231818 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4079 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4339 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
283684 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
322654 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
219888 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
261761 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25780 usd
CY2024Q3 us-gaap Assets
Assets
514731 usd
CY2023Q4 us-gaap Assets
Assets
610195 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
198090 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
264671 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6505 usd
CY2023Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
102040 usd
CY2023Q4 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
12972 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4624193 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4372041 usd
CY2024Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
133222 usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
137028 usd
CY2024Q3 us-gaap Liabilities
Liabilities
4757415 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4509069 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2071000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2071000000 shares
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
85741 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
144509 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32715 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
85664 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
19313 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
77 usd
CY2024Q3 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
65460 usd
CY2023Q3 us-gaap Salaries Wages And Officers Compensation
SalariesWagesAndOfficersCompensation
120865 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
24444 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
61995 usd
us-gaap Professional Fees
ProfessionalFees
91865 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5403 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5372 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5352 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57747 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
65232 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
153054 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
253464 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-133741 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-253387 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-34 usd
CY2024Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4681 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
21028 usd
CY2024Q3 MLRT Interest Expense Income And Financing Costs
InterestExpenseIncomeAndFinancingCosts
-59410 usd
CY2023Q3 MLRT Interest Expense Income And Financing Costs
InterestExpenseIncomeAndFinancingCosts
-155146 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-64091 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-176174 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-197832 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-429561 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-197832 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-429561 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34188322 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34188322 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25838157 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25838157 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33845566 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33845566 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23348693 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23348693 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-4056852 usd
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
12000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-197832 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4242684 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3708292 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3708292 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
22780 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
11896 usd
CY2023Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
347900 usd
CY2023Q3 MLRT Issuance Of Preferred Stock For Financings
IssuanceOfPreferredStockForFinancings
100000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
99850 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-429561 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3555427 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3555427 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3898874 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
59024 usd
MLRT Issuance Of Preferred Stock For Financings
IssuanceOfPreferredStockForFinancings
200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-602834 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-4242684 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3312877 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3312877 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
22780 usd
MLRT Issuance Of Preferred Stock For Financings
IssuanceOfPreferredStockForFinancings
100000 usd
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
99850 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
74211 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
347900 usd
us-gaap Net Income Loss
NetIncomeLoss
-887291 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3555427 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-3555427 usd
us-gaap Net Income Loss
NetIncomeLoss
-602834 usd
us-gaap Net Income Loss
NetIncomeLoss
-887291 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
61369 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
25005 usd
us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
-34 usd
us-gaap Share Based Compensation
ShareBasedCompensation
59024 usd
us-gaap Share Based Compensation
ShareBasedCompensation
22780 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
24917 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
63247 usd
MLRT Gains Losses On Settlement Of Debt And Accrued Interest
GainsLossesOnSettlementOfDebtAndAccruedInterest
-27537 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-16680 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
99850 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6889 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
48177 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6467 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-42815 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-259 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3275 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-150989 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
194450 usd
MLRT Increase Decrease In Account Payable Related Parties
IncreaseDecreaseInAccountPayableRelatedParties
214458 usd
MLRT Increase Decrease In Account Payable Related Parties
IncreaseDecreaseInAccountPayableRelatedParties
171456 usd
MLRT Increase Decrease In Account Payable And Financing Costs
IncreaseDecreaseInAccountPayableAndFinancingCosts
56302 usd
MLRT Increase Decrease In Account Payable And Financing Costs
IncreaseDecreaseInAccountPayableAndFinancingCosts
-50877 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1142 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6400 usd
us-gaap Increase Decrease In Due To Officers And Stockholders Current
IncreaseDecreaseInDueToOfficersAndStockholdersCurrent
600 usd
us-gaap Increase Decrease In Due To Officers And Stockholders Current
IncreaseDecreaseInDueToOfficersAndStockholdersCurrent
30450 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-336174 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-295166 usd
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-42408 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4875 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4875 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
42408 usd
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
46881 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
200000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
100000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
140000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
275000 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
12153 usd
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
29021 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
25930 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
42304 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
301917 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
350556 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39132 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
97798 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68440 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8535 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29308 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
106333 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
74211 usd
MLRT Debt Discount On Convertible Notes
DebtDiscountOnConvertibleNotes
23000 usd
MLRT Debt Discount On Convertible Notes
DebtDiscountOnConvertibleNotes
17150 usd
CY2024Q3 MLRT Working Capital
WorkingCapital
-4340509 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-336174 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
12000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
12000 usd
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
The Company’s warranty policy provides repair or replacement of products (excluding GPS Shoe devices) returned for defects within ninety days of purchase.
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zAUycU34G5Cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_z8naopVtGEnf">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying unaudited financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, estimates related to revenue recognition, allowance for doubtful accounts, inventory valuation, tangible and intangible long-term asset valuation, warranty and other obligations and commitments. Estimates are updated on an ongoing basis and are evaluated based on historical experience and current circumstances. Changes in facts and circumstances in the future may give rise to changes in these estimates which may cause actual results to differ from current estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_z1L6UGuoz68l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_863_z5OlP9lOWt9e">Concentrations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently rely on two manufacturers to supply us with our GPS SmartSole and two manufacturers to supply us with the GPS device included in the GPS SmartSole. The loss of either of these manufacturers could severely impede our ability to manufacture the GPS SmartSole.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently rely on one manufacturer to supply us with our GPS GunAlert and one manufacturer to supply us with the GPS device included in the GPS GunAlert. The loss of this manufacturer could severely impede our ability to manufacture the GunAlert tracking solution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2024, the Company had four customers representing approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zv7drGtEFxdl">35</span>%, <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z6DpvdH9g4k9">17</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z31fRTLB9V3j">12</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zYrPa3Z86Q18">10</span>% of sales, respectively, and four customers representing approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zItCYJ6Ma6cl">17</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9IQS6enSoe5">13</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zH9mV8h3VYul">13</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zo4OSZH0tyO2">13</span>% of total accounts receivable, respectively. As of September 30, 2023, the Company had four customers representing approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcZ8lXTQuL4g">26</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zFrbAtB8ioz4">19</span>%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z7qA6SHBRa08">19</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zm9xVfXLmDqi">14</span>% of sales, respectively, and four customers representing approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zvSFI3O9Z8xh">39</span>%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z8Y3v8shNcUg" title="Concentration risk percentage">22</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zWJKZqes9n5c" title="Concentration risk percentage">19</span>%, and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zpfm0xP4SfKa" title="Concentration risk percentage">6</span>% of total accounts receivable, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
649 usd
CY2024Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
125819179 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
113995239 shares
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
MLRT Investment Owned Description
InvestmentOwnedDescription
The Company’s investments include marketable securities of two entities whereby the Company’s ownership is less than 5%.
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
649 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
649 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
15061 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
24936 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
210290 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
206882 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
225351 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
231818 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
507750 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
488254 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11159 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25780 usd
us-gaap Depreciation
Depreciation
19497 usd
us-gaap Depreciation
Depreciation
25005 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
59577 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
17704 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
219888 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
261761 usd
CY2024Q3 us-gaap Loans Payable Current
LoansPayableCurrent
146195 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
146195 usd
CY2024Q3 us-gaap Line Of Credit
LineOfCredit
7000 usd
CY2023Q4 us-gaap Line Of Credit
LineOfCredit
7000 usd
CY2024Q3 us-gaap Other Borrowings
OtherBorrowings
82886 usd
CY2023Q4 us-gaap Other Borrowings
OtherBorrowings
95040 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
236081 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
248235 usd
CY2022Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000 usd
CY2022Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
120000 usd
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1628000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1490930 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
17750 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
6788 usd
CY2024Q3 us-gaap Debt Current
DebtCurrent
1610250 usd
CY2023Q4 us-gaap Debt Current
DebtCurrent
1484142 usd
CY2024Q3 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
16778 usd
CY2023Q4 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
12972 usd
CY2024Q3 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
133222 usd
CY2023Q4 us-gaap Other Loans Payable Long Term
OtherLoansPayableLongTerm
137028 usd
CY2024Q3 us-gaap Other Loans Payable
OtherLoansPayable
150000 usd
CY2023Q4 us-gaap Other Loans Payable
OtherLoansPayable
150000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
59024 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
846154 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
646154 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
200000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2024Q3 MLRT Bonus Declared Or Accrued
BonusDeclaredOrAccrued
0 usd
CY2023Q3 MLRT Bonus Declared Or Accrued
BonusDeclaredOrAccrued
0 usd

Files In Submission

Name View Source Status
0001493152-24-045769-index-headers.html Edgar Link pending
0001493152-24-045769-index.html Edgar Link pending
0001493152-24-045769.txt Edgar Link pending
0001493152-24-045769-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mlrt-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
mlrt-20240930_def.xml Edgar Link unprocessable
mlrt-20240930_lab.xml Edgar Link unprocessable
mlrt-20240930_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mlrt-20240930_cal.xml Edgar Link unprocessable